Adult patients with newly diagnosed glioma: Dosage during concurrent radiotherapy Oral, 75 mg/m2 daily for 42 days. Receive concurrent radiotherapy, (60GY in 30 doses). Subsequent cycles of adjuvant therapy. Dosage of adjuvant cycle chemotherapy 4 weeks after completion of synchronous radiotherapy, 6-12 cycles of adjuvant therapy at a dose of 150 mg/m2/day for the first cycle. For a total of 5 days, followed by 23 days of discontinuation. The dose after the second cycle is 200 mg/m2/day. Weekly complete blood counts should be performed during treatment. The initial dose of 150 mg/m2 orally once per body surface area once a day for 5 consecutive days in a 28-day treatment cycle is used for each 28-day course of adjuvant chemotherapy. If the absolute neutrophil count (ANC) measured on day 22 and day 29 (the first day of the next cycle) is ≥1.5×109/L and the platelet count is ≥100×109/L, the next cycle dose is 200mg/㎡ orally once a day for 5 days in a 28-day treatment cycle. During the treatment period, the patient’s whole blood count is measured on day 22 (21 days after the first dose) or within 48 hours thereafter, and every week thereafter. If any of the white blood cells, red blood cells, neutrophils, lymphocytes, or platelets are below normal values, the patient should be immediately seen by the hematology department of the local hospital for hematopoietic treatment until the measured absolute neutrophil count (ANC) is ≥1.5× 109/L and platelet count ≥100×109/L, or until the next cycle of treatment under medical supervision. If the measured absolute neutrophil count (ANC) is <1.0×109/L or platelet count is <50×109/L in any treatment cycle, the dose of the next cycle will be reduced by 50mg/㎡, but not lower than the minimum recommended dose of 100mg/㎡. The drug should be taken on an empty stomach (at least half an hour before eating), and antiemetics can be taken before taking temozolomide. Domestic and international guidelines recommend: Temozolomide synchronized radiotherapy plus adjuvant therapy as the first-line standard regimen after newly diagnosed GBM surgery. Synchronized radiotherapy can reduce the risk of disease progression by 46% and the risk of death by 37%, and can improve the 5-year survival rate of patients by 9.8%.